| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Shukla Sanjay serves as a President and CEO at ATYR. Across recent SEC filings that breaks down to 12 buys and 3 sells. Those positions are worth an estimated $150K at current prices.
Historically, Shukla Sanjay's trades have earned a middling insider score of 66/100 across 12 rated trades. Over a 12-month horizon, 58.3% of those trades were profitable, with an average 12-month return of +25.2%.
The biggest single holding is ATYR (~$150K) as President and CEO. Net of sales, the recent Form 4 record there shows accumulation of 108,232 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2021 | ATYR Atyr Pharma Inc | President and CEO | Sale+OE | 778 | $7.66 | $5,959.48 | -8.6% | -50.3% | -21.4% | |
| Jun 19, 2020 | ATYR Atyr Pharma Inc | President and CEO | Buy | 6,000 | $4.27 | $25,620.00 | +464.8% | - | - | |
| Feb 7, 2020 | ATYR Atyr Pharma Inc | President and CEO | Sale+OE | 745 | $4.03 | $3,002.35 | -36.6% | - | - |